🇺🇸 saquinavir/ritonavir in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 14

Most-reported reactions

1. Immune Reconstitution Syndrome — 3 reports (21.43%)
2. Lipoatrophy — 2 reports (14.29%)
3. Nephrolithiasis — 2 reports (14.29%)
4. Acne — 1 report (7.14%)
5. Angina Pectoris — 1 report (7.14%)
6. Body Mass Index Decreased — 1 report (7.14%)
7. Cardiomyopathy — 1 report (7.14%)
8. Central Nervous System Lesion — 1 report (7.14%)
9. Circulatory Collapse — 1 report (7.14%)
10. Communication Disorder — 1 report (7.14%)

Source database →

Frequently asked questions

Is saquinavir/ritonavir approved in United States?

saquinavir/ritonavir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for saquinavir/ritonavir in United States?

International Antiviral Therapy Evaluation Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.